According to the Centers for Disease Control and Prevention, Staphylococcus (staph) bacteria are one of the most common causes of skin infections in the United States. Staph is found in high-traffic facilities such as hospitals, gyms and schools. Some types of the bacteria are drug resistant, generating the need for strict sanitary regulations, as well as the need for the development of treatment to combat bacteria resistant to drugs.
PolyMedix Inc. (PYMX.OB) focuses on the development of products to treat infectious diseases such as staph, as well as acute cardiovascular disorders. The company today announced it will present information of its research and findings at the 2009 Gordon Conference on Antimicrobial Peptides: Understanding Health and Disease through Antimicrobial Host Defense Peptides on Wednesday, March 4 in Ventura, Calif.
Dr. Richard Scott, PolyMedixâ€™s vice president of research, will present the companyâ€™s antibiotic compounds and their efficacy against various drug resistant bacteria. In December 2008, the company released the findings of its phase I human clinical study with PMX 30063, a pan-staph agent for the treatment of numerous forms of staph infections. The study showed that safe and well-tolerated single doses were achieved.
Dr. Scottâ€™s presentation, â€œNonpeptidic Mimics of Host Defense Proteins: Development as IV Antimicrobial Agents,” will center on PolyMedixâ€™s clinical development of PMX-30063.
According to Nicholas Landekic, president and CEO of PolyMedix, bacterial infections have strengthened to resist treatment, and thereâ€™s a growing need for innovative, fresh antibiotics and treatments.
“It is a great honor to be invited to present our findings at the prestigious Gordon Conference. This conference gives us the opportunity to present our work to the leading experts in the field,” Landekic stated in the press release. “Drug resistant bacterial infections are one of the most serious problems facing our world today. There is an urgent need for new treatments, and for resources to be committed to their development. PMX-30063 is intended to directly address the major problem of bacterial drug resistance, and is the first small molecule defensin mimetic for systemic use in clinical development.â€
â€œWe are proud to be the first company to be developing this completely new type of antibiotic, and look forward to continuing with further clinical development of PMX-30063, and other drug candidates,” he concluded.